Good question. The fact that Bristol-Myers Squibb took a major hit in the last quarters earnings, to increase its reserve for legal costs by $110 million, would suggest that the execs are getting prepared for something or the other. Of course I am not the only one to think this way, others do to. There are several analysts quoted in Business Week who seem to believe that Bristol might be getting prepared to settle one of the cases brought against it in the accounting scandal that has clouded its nearterm prospects.
Another negative news, the US Attorney's office in Massachusetts has opened an investigation against marketing Abilify. Hmmmm.
On the positive side, the pipeline is being recognized a bit. A positive article in forbes about it confirms that the Bristol pipeline is better than that of peers in the industry. No wonder, WSJ recently cited BMS as a potential acquisition target for Merck, the injured giant that has its own pipeline woes.
